Article

Updates in the Treatment of Mantle Cell Lymphoma

This article discusses the current treatment landscape and therapeutic strategies for mantle cell lymphoma, the role of Bruton tyrosine kinase inhibitor therapies in MCL, and insights on new regimens and ongoing clinical trials from leading experts in hematologic malignancies.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge
Video

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

May 14th 2025 - May 15th 2026

online-activity
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona

May 13th 2025 - Jun 18th 2025

online-activity
View More
16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™
Video

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

May 9th 2025 - Jun 14th 2025

online-activity
View More
Related Content
R/R Non-Hodgkin Lymphoma | Image Credit: © LASZLO – stock.adobe.com
May 14th 2025

AlloNK Plus Rituximab Induces Durable Responses in R/R B-Cell NHL

Chandler Park, MD, medical oncologist, Norton Cancer Institute; Ann S. LaCasce, MD, MMSc, associate professor, medicine, lymphoma specialist, Dana-Farber Cancer Institute, Director, Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology
March 26th 2025

Strong Mentorship Opportunities Support the Next Generations of Women in Lymphoma: With Chandler Park, MD; and Ann S. LaCasce, MD, MMSc

Mantle cell lymphoma | Image Credit: © Tatiana Shepeleva – stock.adobe.com
May 13th 2025

Large Clonal Hematopoiesis Clones Are Associated With Worse Survival Outcomes in MCL

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

The Inflation Reduction Act Affects Oncology | Image credit: © Valeri Luzina – stock.adobe.com
May 9th 2025

Inflation Reduction Act Leads to Seesaw Effect Between Oncologic Drug Savings and Development

FDA
May 8th 2025

FDA Lifts Clinical Hold on Tabelecleucel Trial for EBV+ Post-Transplant Lymphoproliferative Disease